Interestingly, some of the most potent inhibitors of fXa (e.g., 19h and 22b) achieved single-digit micromolar inhibition potency against AChE and/or BChE, which are well-known drug targets for symptomatic treatment of mild-to-moderate AD. This evidence concerns the gene BCHE and Alzheimer disease.